1
ALL1
CNBX PharmaceuticalsYear
1
ALL1
2020DEALS // DEV.
1
ALL1
DevelopmentsCountry
1
ALL1
U.S.A1
ALL1
Not ApplicableTherapeutic Area
1
ALL1
OncologyStudy Phase
1
ALL1
PreclinicalDeal Type
0
ALLProduct Type
1
ALL1
Small moleculeDosage Form
0
ALLLead Product
1
ALL1
CannabidivarinTarget
0
ALLLead Product(s) : Cannabidivarin
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cannabics Pharmaceuticals Develops Novel Cannabis Formulation for the Treatment of Colon Cancer
Details : The company plans to examine the clinical safety and efficacy of the novel formulation which contains high concentrations of the cannabinoids CBDV and CBGA in a proprietary formulation.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 13, 2020
Lead Product(s) : Cannabidivarin
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?